Top

01-12-2018 | Review

Current concepts and challenges in the radiologic assessment of brain tumors in children: part 2

Authors: Benita Tamrazi, Kshitij Mankad, Marvin Nelson, Felice D’Arco

Published in: Pediatric Radiology | Issue 13/2018

Abstract

Assessing tumor response is a large part of everyday clinical work in neuroradiology. However in the setting of tumor treatment, distinguishing tumor progression from treatment-related changes is difficult on conventional MRI sequences. This is made even more challenging in children where mainstay advanced imaging techniques that are often used to decipher progression versus treatment-related changes have technical limitations. In this review, we highlight the challenges in pediatric neuro-oncologic tumor assessment with discussion of pseudophenomenon including pseudoresponse and pseudoprogression. Additionally, we discuss the advanced imaging techniques often employed in neuroradiology to distinguish between pseudophenomenon and true progressive disease.

Taal W, Brandsma D, de Bruin HG et al (2008) Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 113:405–410CrossRef

Brandsma D, Stalpers L, Taal W et al (2008) Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 9:453–461CrossRef

Verma N, Cowperthwaite MC, Burnett MG, Markey MK (2013) Differentiating tumor recurrence from treatment necrosis: a review of neuro-oncologic imaging strategies. Neuro Oncol 15:515–534CrossRef

Kreisl TN, Kim L, Moore KA et al (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27:740–745CrossRef

Vredenburgh JJ, Desjardins A, Herndon JES et al (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13:1253–1259CrossRef

Wen PY, Macdonald DR, Reardon DA et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963–1972CrossRef

Norden AD, Drappatz J, Muzikansky A et al (2009) An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma. J Neurooncol 92:149–155CrossRef

Negretti L, Blanchard P, Couanet D et al (2012) Pseudoprogression after high-dose busulfan-thiotepa with autologous stem cell transplantation and radiation therapy in children with brain tumors: impact on survival. Neuro Oncol 14:1413–1421CrossRef

Chassot A, Canale S, Varlet P et al (2012) Radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma. J J Neurooncol 106:399–407CrossRef

10.

Ceschin R, Kurland BF, Abberbock SR et al (2015) Parametric response mapping of apparent diffusion coefficient as an imaging biomarker to distinguish pseudoprogression from true tumor progression in peptide-based vaccine therapy for pediatric diffuse intrinsic pontine glioma. AJNR Am J Neuroradiol 36:2170–2176CrossRef

11.

Prager AJ, Martinez N, Beal K et al (2015) Diffusion and perfusion MRI to differentiate treatment-related changes including pseudoprogression from recurrent tumors in high-grade gliomas with histopathologic evidence. AJNR Am J Neuroradiol 36:877–885CrossRef

12.

Hatzoglou V, Ulaner GA, Zhang Z et al (2013) Comparison of the effectiveness of MRI perfusion and fluorine-18 FDG PET-CT for differentiating radiation injury from viable brain tumor: a preliminary retrospective analysis with pathologic correlation in all patients. Clin Imaging 37:451–457CrossRef

13.

Shin KE, Ahn KJ, Choi HS et al (2014) DCE and DSC MR perfusion imaging in the differentiation of recurrent tumour from treatment-related changes in patients with glioma. Clin Radiol 69:e264–e272CrossRef

14.

Essig M, Shiroishi MS, Nguyen TB et al (2013) Perfusion MRI: the five most frequently asked technical questions. AJR Am J Roentgenol 200:24–34CrossRef

15.

Petrella JR, Provenzale JM (2000) MR perfusion imaging of the brain: techniques and applications. AJR Am J Roentgenol 175:207–219CrossRef

16.

Barajas RF, Chang JS, Sneed PK et al (2009) Distinguishing recurrent intra-axial metastatic tumor from radiation necrosis following gamma knife radiosurgery using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. AJNR Am J Neuroradiol 30:367–372CrossRef

17.

Barajas RF, Chang JS, Segal MR et al (2009) Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 253:486–496CrossRef

18.

Carceller F, Fowkes LA, Khabra KS et al (2016) Pseudoprogression in children, adolescents and young adults with non-brainstem high grade glioma and diffuse intrinsic pontine glioma. J Neurooncol 129:109–121CrossRef

19.

Gururangan S, Chi SN, Young Poussaint T et al (2010) Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a pediatric brain tumor consortium study. J Clin Oncol 28:3069–3075CrossRef

20.

Gururangan S, Fangusaro J, Young Poussaint T et al (2012) Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma — a pediatric brain tumor consortium study. Neuro Oncol 14:1404–1412CrossRef

21.

Thompson EM, Guillaume DJ, Dósa E et al (2012) Dual contrast perfusion MRI in a single imaging session for assessment of pediatric brain tumors. J Neurooncol 109:105–114CrossRef

22.

Kruser TJ, Mehta MP, Robins HI (2013) Pseudoprogression after glioma therapy: a comprehensive review. Expert Rev Neurother 13:389–403CrossRef

23.

Parkes LM, Rashid W, Chard DT, Tofts PS (2004) Normal cerebral perfusion measurements using arterial spin labeling: reproducibility, stability, and age and gender effects. Magn Reson Med 51:736–743CrossRef

24.

Patel P, Baradaran H, Delgado D et al (2017) MR perfusion-weighted imaging in the evaluation of high-grade gliomas after treatment: a systematic review and meta-analysis. Neuro Oncol 19:118–127CrossRef

25.

Yoo RE, Choi SH (2016) Recent application of advanced MR imaging to predict pseudoprogression in high-grade glioma patients. Magn Reson Med Sci 15:165–177CrossRef

26.

Welker K, Boxerman J, Kalnin A et al (2015) ASFNR recommendations for clinical performance of MR dynamic susceptibility contrast perfusion imaging of the brain. AJNR Am J Neuroradiol 36:E41–E51CrossRef

27.

Grade M, Hernandez Tamames JA, Pizzini FB et al (2015) A neuroradiologist's guide to arterial spin labeling MRI in clinical practice. Neuroradiology 57:1181–1202CrossRef

28.

Noguchi T, Yoshiura T, Hiwatashi A et al (2008) Perfusion imaging of brain tumors using arterial spin-labeling: correlation with histopathologic vascular density. AJNR Am J Neuroradiol 29:688–693CrossRef

29.

Yeom KW, Mitchell LA, Lober RM et al (2014) Arterial spin-labeled perfusion of pediatric brain tumors. AJNR Am J Neuroradiol 35:395–401CrossRef

30.

Choi YJ, Kim HS, Jahng GH et al (2013) Pseudoprogression in patients with glioblastoma: added value of arterial spin labeling to dynamic susceptibility contrast perfusion MR imaging. Acta Radiol 54:448–454CrossRef

31.

Guo AC, Cummings TJ, Dash RC, Provenzale JM (2002) Lymphomas and high-grade astrocytomas: comparison of water diffusibility and histologic characteristics. Radiology 224:177–183CrossRef

32.

Hayashida Y, Hirai T, Morishita SY et al (2006) Diffusion-weighted imaging of metastatic brain tumors: comparison with histologic type and tumor cellularity. AJNR Am J Neuroradiol 27:1419–1425PubMed

33.

Herneth AM, Guccione S, Bednarski M (2003) Apparent diffusion coefficient: a quantitative parameter for in vivo tumor characterization. Eur J Radiol 45:208–213CrossRef

34.

Asao C, Korogi Y, Kitajima M et al (2005) Diffusion-weighted imaging of radiation-induced brain injury for differentiation from tumor recurrence. AJNR Am J Neuroradiol 26:1455–1460PubMed

35.

Hein PA, Eskey CJ, Dunn JF, Hug EB (2004) Diffusion-weighted imaging in the follow-up of treated high-grade gliomas: tumor recurrence versus radiation injury. AJNR Am J Neuroradiol 25:201–209PubMed

36.

Matsusue E, Fink JR, Rockhill JK et al (2010) Distinction between glioma progression and post-radiation change by combined physiologic MR imaging. Neuroradiology 52:297–306CrossRef

37.

Zeng QS, Li CF, Liu H et al (2007) Distinction between recurrent glioma and radiation injury using magnetic resonance spectroscopy in combination with diffusion-weighted imaging. Int J Radiat Oncol Biol Phys 68:151–158CrossRef

38.

Lee WJ, Choi SH, Park CKH et al (2012) Diffusion-weighted MR imaging for the differentiation of true progression from pseudoprogression following concomitant radiotherapy with temozolomide in patients with newly diagnosed high-grade gliomas. Acad Radiol 19:1353–1361CrossRef

39.

Zarifi M, Tzika AA (2016) Proton MRS imaging in pediatric brain tumors. Pediatr Radiol 46:952–962CrossRef

40.

Martín Noguerol T, Sánchez-González J, Martínez Barbero JP et al (2016) Clinical imaging of tumor metabolism with ¹H magnetic resonance spectroscopy. Magn Reson Imaging Clin N Am 24:57–86CrossRef

41.

Smith EA, Carlos RC, Junck LR et al (2009) Developing a clinical decision model: MR spectroscopy to differentiate between recurrent tumor and radiation change in patients with new contrast-enhancing lesions. AJR Am J Roentgenol 192:W45–W52CrossRef

42.

Elias AE, Carlos RC, Smith EA et al (2011) MR spectroscopy using normalized and non-normalized metabolite ratios for differentiating recurrent brain tumor from radiation injury. Acad Radiol 18:1101–1108CrossRef

43.

Walecki J, Sokól M, Pieniazek P et al (1999) Role of short TE 1H-MR spectroscopy in monitoring of post-operation irradiated patients. Eur J Radiol 30:154–161CrossRef

44.

Dhermain FG, Hau P, Lanfermann H et al (2010) Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. Lancet Neurol 9:906–920CrossRef

45.

Alexander A, Murtha A, Abdulkarim B et al (2006) Prognostic significance of serial magnetic resonance spectroscopies over the course of radiation therapy for patients with malignant glioma. Clin Invest Med 29:301–311PubMed

46.

Quon H, Brunet B, Alexander AW et al (2011) Changes in serial magnetic resonance spectroscopy predict outcome in high-grade glioma during and after postoperative radiotherapy. Anticancer Res 31:3559–3565PubMed

47.

Cha J, Kim ST, Kim HJ et al (2014) Differentiation of tumor progression from pseudoprogression in patients with posttreatment glioblastoma using multiparametric histogram analysis. AJNR Am J Neuroradiol 35:1309–1317CrossRef

48.

Park JE, Kim HS, Goh MJ et al (2015) Pseudoprogression in patients with glioblastoma: assessment by using volume-weighted voxel-based multiparametric clustering of MR imaging data in an independent test set. Radiology 275:792–802CrossRef

49.

Caroline I, Rosenthal MA (2012) Imaging modalities in high-grade gliomas: pseudoprogression, recurrence, or necrosis? J Clin Neurosci 19:633–637CrossRef

50.

Terakawa Y, Tsuyuguchi N, Iwai Y et al (2008) Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. J Nucl Med 49:694–699CrossRef

51.

Galldiks N, Dunkl V, Stoffels GJ et al (2015) Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PET. Eur J Nucl Med Mol Imaging 42:685–695CrossRef

52.

Batchelor TT, Sorensen AG, di Tomaso E et al (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83–95CrossRef

53.

Melhem ER, Mehta NR (1999) Dynamic T1-weighted spin-echo MR imaging: the role of digital subtraction in the demonstration of enhancing brain lesions. J Magn Reson Imaging 9:503–508CrossRef

54.

Kanaly CW, Ding D, Mehta AI et al (2011) A novel method for volumetric MRI response assessment of enhancing brain tumors. PLoS One 6:e16031CrossRef

55.

Ellingson BM, Kim HJ, Woodworth DC et al (2014) Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology 271:200–210CrossRef

56.

Sorensen AG, Batchelor TT, Zhang WT et al (2009) A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res 69:5296–5300CrossRef

57.

Galldiks N, Law I, Pope WB et al (2017) The use of amino acid PET and conventional MRI for monitoring of brain tumor therapy. Neuroimage Clin 13:386–394CrossRef

58.

Galldiks N, Filss CP, Goldbrunner R, Langen KJ (2012) Discrepant MR and [(18)F]fluoroethyl-L-tyrosine PET imaging findings in a patient with bevacizumab failure. Case Rep Oncol 5:490–494CrossRef

59.

Galldiks N, Rapp M, Stoffels G et al (2013) Earlier diagnosis of progressive disease during bevacizumab treatment using O-(2-18F-fluorethyl)-L-tyrosine positron emission tomography in comparison with magnetic resonance imaging. Mol Imaging 12:273–276CrossRef

60.

Aquino D, Gioppo A, Finocchiaro G et al (2017) MRI in glioma immunotherapy: evidence, pitfalls, and perspectives. J Immunol Res 2017:5813951CrossRef

61.

Vrabec M, Van Cauter S, Himmelreich U et al (2011) MR perfusion and diffusion imaging in the follow-up of recurrent glioblastoma treated with dendritic cell immunotherapy: a pilot study. Neuroradiology 53:721–731CrossRef

Title: Current concepts and challenges in the radiologic assessment of brain tumors in children: part 2
Authors: Benita Tamrazi
Kshitij Mankad
Marvin Nelson
Felice D’Arco
Publication date: 01-12-2018
Publisher: Springer Berlin Heidelberg
Published in: Pediatric Radiology / Issue 13/2018
Print ISSN: 0301-0449
Electronic ISSN: 1432-1998
DOI: https://doi.org/10.1007/s00247-018-4232-7

ACC 2024 Congress

Springer Medicine

Current concepts and challenges in the radiologic assessment of brain tumors in children: part 2

Abstract

ACC 2024 Congress

Springer Medicine

Abstract

Please log in to get access to this content